Invivogen
Menu

AddaS03™ Adjuvant

Product Unit size Cat. code Docs. Qty. Price

AddaS03™

Oil-in-water nano-emulsion adjuvant

Show product

10 mL

vac-as03-10
+-
$283

Vaccine Adjuvant: Squalene emulsion

Composition and immune responses to AddaS03™
Composition and immune responses to AddaS03™

AddaS03™ is an oil-in-water nano-emulsion adjuvant, with a formulation similar to that of the adjuvant system AS03®, a fundamental component of pandemic influenza and protein-based covid vaccines [approved by relevant regulatory authorities] [1]. It is composed of the same percentage of two biodegradable oils, squalene and DL-α-tocopherol, and the surfactant, polysorbate 80 (Tween® 80), for increased stability. Squalene oil-in-water emulsions, such as MF59® or AS03®, allow for antigen dose sparing and result in mixed cell-mediated and humoral immune responses (Th1/Th2) [2-5]. A consistent signature pattern of early post-vaccine activation of myeloid and lymphoid cells following the administration of these adjuvants has emerged across multiple studies in humans [1].

 

AddaS03™ is VacciGrade™, a high-quality pre-clinical grade.

AddaS03™ is for research use only, and not for human or veterinary use.

 

Note: AS03® is a registered trademark of GSK, and is used for comparative purposes only. AddaS03™ is not made by, affiliated with, sponsored by, or endorsed by GSK. GSK has not evaluated or approved the representations contained herein.

Read our review Read our review on Vaccine Adjuvants

 

References:

1. O'Hagan, DT. et al. 2021. "World in motion" - emulsion adjuvants rising to meet the pandemic challenges. npj vaccines 6(1):158.
2. Morel, S. et al. 2011. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29:2461.
3. Calabro, S. et al., 2013. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 31:3363.
4. Wilkins, AL et al., 2017. AS03- and MF59-Adjuvanted Influenza Vaccines in Children. Front Immunol 8:1760.
5. Shi, S. et al. 2019. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine 37:3167.

Back to the top

Specifications

VacciGrade™ (preclinical grade)

Formulation: AddaS03™ is a nano-emulsion of DL-α-tocopherol (5% v/v) in squalene oil 5% (v/v) and Tween® 80 (1.8% v/v) in PBS (pH 6.8)

Note: The nano-emulsion is produced using a microfluidizer and filtered through a 0.22-µm filter to remove any large droplets and sterilize the final product. 

Quality control:

  • Sterility guaranteed 
  • Endotoxin level < 10 EU/ml (determined using the HEK-Blue™ LPS Detection Kit 2)
  • AddaS03™ physio-chemical characteristics have been confirmed by sizing (determined by the dynamic light scattering method) and HPLC.

 

Back to the top

Contents

  • 10 ml AddaS03™, provided as a ready-to-use sterile nano-emulsion

 

 AddaS03™ is shipped at room temperature.

 Upon receipt,  AddaS03™ should be stored at 4°C.

 DO NOT FREEZE.

 

Back to the top

VacciGrade™

VacciGrade™ is a high-quality pre-clinical grade. VacciGrade™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room*. The absence of bacterial contamination is assessed by a sterility test using a pharmacopeia-derived assay. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and/or a TLR2 and TLR4 reporter assay.
*Except for LPS VacciGrade™, which is prepared in a laminar flow hood dedicated to LPS.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty